Viroblock has a strong IP position on a very simple technology. Specifically, Viroblock has created patented formulation non-phospholipid /cyclodextrin combinations. These formulae can be liquid or semi-solid or solid forms and all rapidly inactivate (kill) enveloped viruses.

Non-phospholipids are esters of long chain fatty acids and are commonly found in cosmetics, skin care, hair care and other consumer health products. Cyclodextrins are similarly well known and are frequently used in pharmaceuticals as non-active ingredients. When appropriately formulated the non-phospholipids can form vesicles which have strong anti-viral properties when combined with specific cyclodextrin.

Because the technology targets cholesterol and not a gene product, Viroblock products are broad spectrum (e.g., all enveloped viruses tested so far are susceptible) and do not create resistance. This means that multiple pathogenic viruses such as H1N1, H5N1, RSV, Herpes Simplex Virus, HIV, SARS, etc., can all be killed by Viroblock products.

Finally, cholesterol depletion is extremely fast. This is opening the way to making products that can kill air borne viruses during the fraction of a second it takes for them to pass through a filter.